Quintrio
Home

Stock overview

SciSparc Ltd. Ordinary Shares

SPRC

SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.313 – $0.35
Volume 43,779
Market cap $1M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for SPRC.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for SPRC.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Why Is SciSparc Stock Skyrocketing On Thursday?

SciSparc Ltd. (NASDAQ: SPRC) stock surged 157% on Thursday following a pre-market announcement that its majority-owned subsidiary NeuroThera Labs Inc. received conditional regulatory approval from the TSX Venture Exchange. The approval clears the path for NeuroThera to acquire a 54% majority stake in CliniQuantum Ltd., an Israeli technology company that develops quantum simulation platforms for clinical trial data analysis. The deal, valued at approximately $9.459 million, aims to improve precision in clinical trial outcomes by identifying patient subpopulations responsive to investigational therapies.

Benzinga

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

SciSparc's majority-owned subsidiary NeuroThera Labs has signed a definitive agreement to acquire approximately 54% of CliniQuantum, a quantum technology company specializing in quantum-based clinical trials. NeuroThera will issue 56.6 million common shares valued at approximately $9.46 million, with potential earn-out payments up to $2.5 million based on patent filings and fundraising milestones. The transaction is expected to close by March 31, 2026.

Benzinga

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Ltd. has entered into an agreement to acquire a controlling interest in Miza III Ventures Inc., transferring its advanced clinical stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. The transaction values the target assets at approximately $11.6 million and is expected to close around October 22, 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 4, 20261-for-9reverse split
Jul 3, 20251-for-21reverse split
Sep 28, 20231-for-26reverse split